BSD Medical Corporation (NASDAQ:BSDM) (the “Company” or “BSD”) announced today that the Company has significantly expanded the MicroThermX
Microwave Ablation System (MicroThermX
) market opportunity by introducing a new SynchroWave short tip (ST) antenna. The SynchroWave ST antenna can be used to deliver smaller, spherical ablation zones that more accurately target smaller areas of diseased tissue (tumors). The existing SynchroWave LT (Long Tip) antenna delivers larger ablation zones, reducing the need for multiple ablations on larger tumors. The multiple configurations of the SynchroWave antenna provide physicians the ability to precisely target the ablation zone to the numerous sizes and shapes of diseased tissue, significantly increasing the number of cases that can be treated with the MicroThermX
. The MicroThermX
continues to allow non-parallel placement of multiple antennas with one generator and flexibility in approach angles for placement of antennas in difficult to reach areas.
The ability to easily and precisely ablate a wide range of tumors is required for successful clinical use of microwave ablation. The introduction of multiple SynchroWave antenna configurations allows the Company to market products that meet the needs of the entire interventional radiology marketplace.
About BSD Medical Corporation
BSD Medical Corporation develops, manufactures, markets and services systems to treat cancer and benign diseases using heat therapy delivered using focused radiofrequency (RF) and microwave energy. BSD’s product lines include both hyperthermia and ablation treatment systems. BSD’s hyperthermia cancer treatment systems, which have been in use for several years in the United States, Europe and Asia, are used to treat certain tumors with heat (hyperthermia), while increasing the effectiveness of other therapies such as radiation therapy. BSD’s microwave ablation system has been developed as a stand-alone therapy to employ precision-guided microwave energy to ablate (destroy) soft tissue and has received marketing clearance from the U.S. FDA. The Company has developed extensive intellectual property, multiple products in the market and established distribution in the United States, Europe and Asia. Certain of the Company’s products have received regulatory approvals and clearances in the United States, Europe and China. For further information visit BSD Medical's website at
Statements contained in this press release that are not historical facts are forward-looking statements, as defined in the Private Securities Litigation Reform Act of 1995. All forward-looking statements are subject to risks and uncertainties detailed in the Company's filings with the Securities and Exchange Commission. These forward-looking statements speak only as of the date on which such statements are made, and the Company undertakes no obligation to update such statements to reflect events or circumstances arising after such date.